1. Site-Specific DNA–Doxorubicin Conjugates Display Enhanced Cytotoxicity to Breast Cancer Cells
- Author
-
Christopher H. Stuart, David A. Horita, Michael J. Thomas, Freddie R. Salsbury, Mark O. Lively, and William H. Gmeiner
- Subjects
Magnetic Resonance Spectroscopy ,Molecular model ,media_common.quotation_subject ,Biomedical Engineering ,Pharmaceutical Science ,Breast Neoplasms ,Bioengineering ,Article ,chemistry.chemical_compound ,Cell Line, Tumor ,polycyclic compounds ,medicine ,Humans ,Doxorubicin ,Internalization ,Cytotoxicity ,media_common ,Pharmacology ,Cardiotoxicity ,Antibiotics, Antineoplastic ,Organic Chemistry ,DNA ,3. Good health ,Biochemistry ,chemistry ,Covalent bond ,Female ,Biotechnology ,Conjugate ,medicine.drug - Abstract
Doxorubicin (Dox) is widely used for breast cancer treatment but causes serious side- effects including cardiotoxicity that may adversely impact patient lifespan even if treatment is successful. The present invention relates to selective conjugation of Dox to a single site in a DNA hairpin resulting in a highly stable complex that enables Dos to be used more effectively. Selective conjugation of Dox to G15 in the hairpin loop was verified using site-specific labeling with [2- 15N3-2'-deoxyguanosme in conjunction with [1 H-15NJ 2D NM R while 1:1 stoichiometry for the conjugate was validated by ESI-QTOF mass spectrometry and UV spectroscopy. Molecular modeling indicated covalently bound Dox also intercalated into the stem of the hairpin and stability studies demonstrated the resulting Dox-conjugated hairpin (DCH) complex had a half-life > 30 h, considerably longer than alternative covalent and non- covalent complexes. Secondary conjugation of DCH with folic acid (FA) resulted in increased internalization into breast cancer cells. The dual conjugate, DCH-FA, can be used tor safer and more effective chemotherapy with Dox and this conjugation strategy can be expanded to include additional anti-cancer drugs.
- Published
- 2014
- Full Text
- View/download PDF